At the IDWeek infectious diseases conference in Washington, infectious disease specialist Paul G. Auwaerter of the Johns Hopkins University School of Medicine presented Phase 3 data on the Lyme disease vaccine candidate LB6V, which Pfizer and Valneva are jointly developing. From 28 days after the fourth and final dose, the vaccine showed 73.2 percent efficacy against confirmed Lyme disease cases compared with placebo, with a 95 percent confidence interval of 15.8 to 93.5 percent. People aged five and older were studied in a randomized, placebo-controlled, observer-blinded trial. The trial thus narrowly missed the required statistical success criterion: The lower bound of the confidence interval would have had to exceed 20 percent. Auwaerter attributed this to a limited number of disease cases. Nevertheless, he described the efficacy as clinically meaningful and the vaccine as safe with a favorable side effect profile.
H2 Vaccination schedule and mechanism of action
The vaccine candidate tested in the VALOR trial is now called LB6V, was previously called VLA15 and has the development designation PF-07307405. The specialist publication Rheumatology Advisor describes the mechanism of action as follows: When feeding on blood, a tick takes up the antibodies produced through vaccination, which bind to the bacteria and prevent them from moving from the tick into the human body. According to the trial registry ClinicalTrials.gov, participants were to receive three doses for primary immunization at approximately 0, 2 and 5 to 9 months, followed by a booster around 12 months later, timed to coincide with the start and peak of the respective Lyme disease season. The number of people enrolled varies by source: The trial registry lists 12,546 participants, Rheumatology Advisor 12,547, Healio just under 10,000 enrolled and 8,011 trial completions, and the protocol description around 9,400 planned participants, excluding eight trial sites closed because of quality problems.

More illnesses associated with tick bites in the United States, no commercial Lyme disease vaccine
In an article published in March 2026, Lars Eisen writes that diseases transmitted through tick bites are increasing in the United States because vector species such as the blacklegged tick and the lone star tick have expanded their geographic range. Personal protection against tick bites and tick control in the environment, as currently applied, have so far failed to halt the rise in the number of people bitten, Eisen writes. The U.S. health agency CDC recorded more than 89,000 reported Lyme disease cases in 2023, according to ABC News, but estimates the actual number of people diagnosed and treated annually at around 476,000, while European countries with surveillance systems report about 132,000 cases annually, according to the specialist publication Contagion Live. A commercial Lyme disease vaccine is currently unavailable, Auwaerter said: LB6V is intended to fill precisely this gap.
The discontinued predecessor and outstanding criticism
There was an approved vaccine once before: LYMErix entered the U.S. market in 1998 and was withdrawn by GSK in 2002 after reports of side effects led to poor sales. Those reports later proved to be inaccurate. Eugene Shapiro told ABC News that low demand and weak sales had led to its discontinuation at the time, and that the current vaccine closely resembled the old one, with minor changes. According to Shapiro, the CDC advisory committee at the time had recommended considering vaccination for people at higher risk; it had not been recommended for people at low or no risk. Several studies did not substantiate concerns raised about joint problems in recipients of the earlier vaccine, explained Martin Becker, clinical associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine. On the current results, Shapiro said, according to Healio, that these were the same data presented in March, with a few more numbers. He called the results encouraging but criticized the lack of discussion of efficacy in the first year. He also questioned how willing people would be to wait 18 months for vaccine protection. Auwaerter disclosed receiving research support from Pfizer, while Shapiro stated that he receives royalties from UpToDate.
According to Medical Daily, Pfizer planned, subject to further positive data, to submit applications for approval to the U.S. agency FDA and the European Medicines Agency in 2026. Valneva had said the previous year that, if approved, it expected Pfizer to launch the vaccine in the second half of 2027. In his presentation in October, Auwaerter mentioned neither possible approval nor a market launch. Whether the vaccine will fill the gap left by the withdrawal of LYMErix in 2002 remains open; Shapiro points out in this context that the results presented did not address efficacy in the first year.
